Sitafloxacin

Drug Profile

Sitafloxacin

Alternative Names: DU 6859; DU-6859a; Gracevit; Sitafloxacin hydrate

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Fluoroquinolones
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 28 Jun 2013 Daiichi Sankyo plans a phase I trial in Healthy volunteers in China
  • 22 Apr 2013 Launched prior to this date for Bacterial infections in Thailand (PO)
  • 05 Jun 2008 Discontinued - Phase-II for Bacterial infections in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top